Neovascular AMD: Bevacizumab Injection Increases Angiogenic Biomarkers

Dr. Thiago Cabral

Neovascular age-related macular degeneration (nAMD) is induced by the development of new abnormal ‘leaky’ blood vessels in the choroid and retina, when the balance of pro- and anti-angiogenic factors is upset. Vascular endothelial growth factor (VEGF) is considered a critical modulator of angiogenesis and is related to induction of endothelial cell migration and proliferation after hypoxia. The development of anti-VEGF agents, such as bevacizumab (Avastin®), ranibizumab (Lucentis®) and aflibercept (Eylea®), revolutionized the treatment of nAMD.

Regeneron's PANORAMA study for Eylea in Diabetic Retinopathy shows Promise

(c) PMLive

Regeneron Pharmaceuticals, Inc. announced positive topline data from its Phase III PANORAMA clinical trial of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy. Diabetic retinopathy, which affects about eight million people, is the result of microvascular damage to the blood vessels in the retina related to lack of blood sugar control in diabetic patients.

Researchers identify a key protein in Diabetic Retinopathy

Researchers at University of Utah Health have identified a protein, ADP-ribosylation factor 6 (ARF6), which is crucial for the development of diabetic retinopathy. Published in The Journal of Clinical Investigation, they identified a compound, NAV-2729, which inhibits or blocks ARF6, reducing the chances of development of diabetic retinopathy.

EYLEA gets FDA approval for wet AMD, Diabetic macular edema and macular edema following retinal vein occlusion

Regeneron Pharmaceuticals, Inc. has announced that Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection for the treatment of Macular Edema following Retinal Vein Occlusion (RVO), which includes Macular Edema following Branch Retinal Vein Occlusion (BRVO) in addition to the previously-approved indication of Macular Edema following Central Retinal Vein Occlusion (CRVO). 

EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME)

Regeneron Pharmaceuticals, Inc. have announced that US FDA has approved EYLEA® (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). 

The recommended dosage of EYLEA in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. Although EYLEA may be dosed as frequently as 2 mg every 4 weeks, additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks.

EYLEA is the first VEGF inhibitor approved for dosing on a less than monthly basis for the treatment of DME.